More about

Car T-Cell Therapy

News
October 30, 2023
2 min read
Save

CAR-T outcomes for multiple myeloma similar regardless of race, ethnicity

CAR-T outcomes for multiple myeloma similar regardless of race, ethnicity

Black, Hispanic and white individuals treated with idecabtagene vicleucel for relapsed or refractory multiple myeloma experienced similar PFS and OS, according to study results published in Blood Advances.

News
October 13, 2023
1 min read
Save

FDA clears third IND for Kyverna’s CAR T-cell drug to treat systemic sclerosis

FDA clears third IND for Kyverna’s CAR T-cell drug to treat systemic sclerosis

The FDA has approved an investigational new drug application for Kyverna Therapeutics’ KYV-101, an anti-CD19 chimeric antigen receptor T-cell therapy for diffuse cutaneous systemic sclerosis, according to a company press release.

News
October 11, 2023
3 min read
Save

Aggressive management may lead to fewer cardiac events after CAR T-cell therapy

Aggressive management may lead to fewer cardiac events after CAR T-cell therapy

Adults undergoing chimeric antigen receptor T-cell therapy are at low risk for major adverse cardiovascular events, according to data published in JACC: CardioOncology.

News
October 03, 2023
1 min read
Save

FDA clears third IND for Cabaletta’s CAR T-cell drug; trial will enroll patients with SSc

FDA clears third IND for Cabaletta’s CAR T-cell drug; trial will enroll patients with SSc

The FDA has granted an investigational new drug application for CABA-201, a 4-1BB-containing fully human CD19-CAR T-cell therapy, to be studied in patients with systemic sclerosis, according to a press release from its manufacturer.

News
September 10, 2023
1 min read
Save

‘A very exciting time’: Voclosporin, cell therapies represent future of lupus treatment

‘A very exciting time’: Voclosporin, cell therapies represent future of lupus treatment

SAN DIEGO —The recent voclosporin approval and continued research into cell therapies make this a “very exciting time” for lupus nephritis therapy, according to a speaker 2023 Congress of Clinical Rheumatology West.

News
September 09, 2023
2 min read
Save

Sustained MRD negativity after CAR-T improves outcomes in multiple myeloma

Sustained MRD negativity after CAR-T improves outcomes in multiple myeloma

Patients with multiple myeloma who exhibited sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel achieved longer PFS and duration of response, according to study results.

News
August 28, 2023
3 min read
Save

CAR T cells in autoimmunity: A potential breakthrough about to explode

CAR T cells in autoimmunity: A potential breakthrough about to explode

First and foremost, I want to remind you that this is an editorial, which by definition offers an “opinion,” so I don’t want to be pilloried for overstating data or brandishing irrational enthusiasm.

News
August 28, 2023
12 min read
Save

Small study, seismic implications: Exploring the promise, challenges of CAR T in lupus

Small study, seismic implications: Exploring the promise, challenges of CAR T in lupus

It is not often that a single data set has the potential to fundamentally alter the treatment landscape for a disease in rheumatology, but recent findings on the use of chimeric antigen receptor T-cells in lupus may eventually do just that.

News
August 28, 2023
2 min read
Save

FDA grants priority review to myelodysplastic syndrome, prostate cancer therapies

FDA grants priority review to myelodysplastic syndrome, prostate cancer therapies

The FDA announced several regulatory actions the past few weeks.

News
August 23, 2023
2 min watch
Save

VIDEO: Novel agents in the multiple myeloma pipeline

View more